Back to Investors

Investment Case

A diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology Manufacturers, Uniphar represents a strong combination of scale, growth and profitability.

In 2025, the Group generated revenue of €3.1bn, gross profit of €458m and EBITDA of €131m. With a workforce of more than 3,500, the Group is active in Ireland, Europe, USA, APAC and MENA.

Click here to learn more